Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Return on Retained Earnings (RORE) is an indicator of a company's growth potential, it shows how much a company earns by reinvesting its retained earnings, i.e. profits after dividend payments.
Applied BioCode's 3-Year RORE % for the quarter that ended in Dec. 2025 was 0.52%.
The industry rank for Applied BioCode's 3-Year RORE % or its related term are showing as below:
TPE:6598's 3-Year RORE % is ranked better than 55.47% of 777
companies
in the Medical Devices & Instruments industry
Industry Median: -4.07
vs TPE:6598: 0.52
Return on Retained Earnings (RORE) is important to investors because it reveals a company's efficiency and growth potential. A higher RORE indicates a higher return. A high RORE indicates that the company should reinvest profits into the business. A lower RORE suggests that the company should distribute profits to shareholders by paying out dividends, since those dollars aren't generating much additional growth for the company.
There are a several different ways to arrive at the Return on Retained Earnings. The simplest way to calculate it is by using published information on Earnings per Share (EPS) and Dividend per Share (DPS) over a selected period. Here, 3-year period is chosen.
Be Aware
Please keep in mind that the RORE is relative to the nature of the business and its competitors. If another company in the same sector is producing a lower return on retained earnings, it doesn’t necessarily mean it’s a bad investment. It may just suggest the company is older and no longer in a high growth stage. At such a stage in the business cycle, it would be expected to see a lower RORE and higher dividend payout.
Applied BioCode 3-Year RORE % Related Terms
Applied BioCode 3-Year RORE % Historical Data
* Premium members only.
The historical data trend for Applied BioCode's 3-Year RORE % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
TPE:6598 vs ABT, SYK, MDT: 3-Year RORE % Comparison
For the Medical Devices subindustry, Applied BioCode's 3-Year RORE %, along with its competitors' market caps and 3-Year RORE % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Applied BioCode 3-Year RORE % vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Applied BioCode's 3-Year RORE % distribution charts can be found below:
* The bar in red indicates where Applied BioCode's 3-Year RORE % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of 3-Year RORE %, the most recent and first period EPS (Diluted) is the trailing twelve months (TTM) data ended in Dec. 2025 and 3-year before.
Applied BioCode (TPE:6598) has a 3-Year RORE % of 0.52 as of Dec. 2025. 3-Year RORE % shows how much a company earns by reinvesting its retained earnings in 3-year. View historical data on Applied BioCode and its competitors. According to the industry distribution chart, Applied BioCode ranks #346 out of 777 companies in the Medical Devices & Instruments industry, placing it in the top 44.5%.
Is Applied BioCode's 3-Year RORE % too high?
Applied BioCode's current 3-Year RORE % is 0.52. Based on the distribution chart, Applied BioCode ranks #346 out of 777 companies in the Medical Devices & Instruments industry, which is above the industry midpoint. Overall, Applied BioCode has a GF Score™ of 75/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Applied BioCode's 3-Year RORE % compare to ABT and SYK?
According to the Medical Devices & Instruments industry distribution chart, Applied BioCode ranks #346 out of 777 companies for 3-Year RORE %. This puts Applied BioCode in the upper half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-Year RORE % for a Medical Devices & Instruments company?
A good 3-Year RORE % depends on the Medical Devices & Instruments industry context. However, 3-Year RORE % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-Year RORE % mean?
A high 3-Year RORE % can signal that a stock is expensive relative to its fundamentals. 3-Year RORE % shows how much a company earns by reinvesting its retained earnings in 3-year. View historical data on Applied BioCode and its competitors. Applied BioCode's current 3-Year RORE % is 0.52. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Applied BioCode stock overvalued right now?
Based on GuruFocus' analysis, Applied BioCode (TPE:6598) is currently considered Modestly Overvalued. The stock's GF Value™ is NT$23.34, compared to a current price of NT$27.65 — trading 18.5% above its estimated fair value. The current 3-Year RORE % is 0.52. Applied BioCode's overall GF Score™ is 75/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-Year RORE % calculated?
3-Year RORE % is calculated from a company's financial statements. For Applied BioCode (TPE:6598), the current 3-Year RORE % is 0.52 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Applied BioCode (TPE:6598) Overvalued in 2026?
Based on GuruFocus' analysis, Applied BioCode stock appears to be overvalued.
The current stock price of NT$27.65 is trading 18.5% above its estimated GF Value™ of NT$23.34.
GuruFocus considers Applied BioCode to be Modestly Overvalued.
Key valuation signals for TPE:6598:
3-Year RORE %: 0.52
GF Value™: NT$23.34 vs. price of NT$27.65 (18.5% above fair value)
No single metric tells the full story. See the TPE:6598 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Applied BioCode Corp is engaged in designing, developing, manufacturing, and commercializing multiplex testing products for the in-vitro diagnostics market. The company's in-vitro diagnostic products focus on the molecular infectious disease segment of the market with assays that detect pathogens for gastrointestinal tract infections, respiratory infections, and sexually transmitted infections. The firm's products include barcoded magnetic bead technology (BMB). The BMB technology and detection systems assist in the development of multiplexed nucleic acids or protein detection assays. The company also develops applications for other areas of the diagnostics industry including life science research, agricultural testing, and veterinary markets.
75GF Score
Get the complete analysis for TPE:6598
3-Year RORE % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
TPE:6598 has been successfully added to your 
